Successful delivery of the HuR CRISPR plasmid via omSLN-HAR and DTX by omLip-HAR could regulate apoptosis, EGFR, Wnt-activated, MDR, and EMT signaling pathways, and consequently effectively inhibit tumor growth and reduce systemic adverse effects in TNBC in vitro and in vivo. Here, LYVE1 is linked to neoplasm.